Yichang East Sunshine Changjiang Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical is a leading Chinese pharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic products in the anti-viral, endocrine, and cardiovascular segments. The company is best known for its flagship product, Kewei (oseltamivir phosphate), which holds a dominant market share in China's influenza treatment market. Beyond its antiviral success, the company has built a comprehensive metabolic disease portfolio, including various insulin analogues and SGLT2 inhibitors. As a core subsidiary of the HEC Group, it leverages integrated manufacturing and R&D capabilities to expand into innovative drug development and complex generics. The company is listed on the Hong Kong Stock Exchange and continues to focus on high-growth therapeutic areas within the Chinese healthcare market.